Andelen patienter som hade minst 50% reduktion av basal UACR vid slutmålet var 24, 7% och 12, 5% för Tekturna respektive placebo. ###>The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for Tekturna and placebo, respectively.